No Data
Hefei Lifeon Pharmaceutical (003020.SZ): plans to use the remaining raised funds to permanently supplement working capital.
On December 9, 2023, Hefei Lifeon Pharmaceutical (003020.SZ) announced that the fifth board of directors held its seventeenth meeting and the fifth supervisory board held its fifteenth meeting on December 9, 2024, which reviewed and approved the proposal on the permanent use of surplus raised funds to supplement working capital. It agreed to permanently supplement working capital with surplus raised funds after the completion of the fundraising investment projects for the company's daily production and operation. This proposal needs to be submitted to the company's shareholders' meeting for approval. Given that the company's fundraising investment projects have reached the planned usable status, and the payment cycle for the performance bond and final payment for the fundraising investment projects is long, in order to provide.
Hefei Lifeon Pharmaceutical (003020.SZ) 2024 mid-term profit distribution plan: proposes to distribute 2 yuan for every 10 shares.
On December 9, Gelonghui reported that hefei lifeon pharmaceutical (003020.SZ) announced the proposed profit distribution plan for the first half of 2024 as follows: The profit distribution will be based on the total share capital as of the date of the rights distribution. The company plans to distribute a cash dividend of 2 yuan (tax included) for every 10 shares to all shareholders. Based on this preliminary calculation, the total cash dividend proposed to be distributed is 38,252,100 yuan (tax included).
Chinese Drug Regulator Accepts Lifeon Pharmaceutical's Listing Application for Asartan Potassium
Hefei Lifeon Pharmaceutical (003020.SZ): The application for the listing of the active pharmaceutical ingredient Valsartan Potassium in the United States has been accepted.
On November 26, Gelonghui reported that hefei lifeon pharmaceutical (003020.SZ) announced that recently, Hefei Lifeon Pharmaceutical Co., Ltd. received the "Acceptance Notice" for the market application of the active pharmaceutical ingredient for Mesilate Potassium issued by the National Medical Products Administration. Mesilate Potassium is a prodrug that can be rapidly converted into the active ingredient Azilsartan after oral absorption, and its formulation is used to treat adult primary hypertension, developed by Takeda Pharmaceutical Company Limited. This product is a raw material used for generic formulations of pharmaceuticals that have already been marketed in the domestic market.
Hefei Lifeon Pharmaceutical's (SZSE:003020) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Cube Pharmaceuticals: Report for the third quarter of 2024
Investors Don't See Light At End Of Hefei Lifeon Pharmaceutical Co., Ltd.'s (SZSE:003020) Tunnel And Push Stock Down 27%